Skip to main content
OpenTrials

Clinical trial condition

Communicable Diseases

Explore clinical trials studying Communicable Diseases. Study availability and eligibility vary by location and protocol.

9,170 public trials 550 recruiting studies
Refine in advanced search Browse all conditions

Communicable Diseases trial results

Completed

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 1)

NCT01343888

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +8 more
Locations
  • 1220.30.4303 Boehringer Ingelheim Investigational Site Linz, Austria
  • 1220.30.4301 Boehringer Ingelheim Investigational Site Vienna, Austria
  • 1220.30.4302 Boehringer Ingelheim Investigational Site Vienna, Austria
  • 1220.30.4304 Boehringer Ingelheim Investigational Site Vienna, Austria
View all 98 locations
View Trial Details
Completed

UNITY 3: A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 in Subjects With Genotype 1 Chronic Hepatitis C

NCT02123654

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +9 more
Locations
  • Local Institution Nagoya, Aichi-ken, Japan
  • Local Institution Nagoya, Aichi-ken, Japan
  • Local Institution Fukui-shi, Fukui, Japan
  • Local Institution Fukuoka, Japan
View all 35 locations
View Trial Details
Completed

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)

NCT01297270

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +8 more
Locations
  • 1220.47.0004 Boehringer Ingelheim Investigational Site Birmingham, Alabama, United States
  • 1220.47.0045 Boehringer Ingelheim Investigational Site Birmingham, Alabama, United States
  • 1220.47.0050 Boehringer Ingelheim Investigational Site Dothan, Alabama, United States
  • 1220.47.0061 Boehringer Ingelheim Investigational Site Phoenix, Arizona, United States
View all 106 locations
View Trial Details
Completed

Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin)

NCT01017575

Conditions
Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +9 more
Locations
  • Local Institution Chiba, Japan
  • Local Institution Kurume-Shi, Fukuoka, Japan
  • Local Institution Okayama, Okayama-ken, Japan
  • Local Institution Osaka, Japan
View Trial Details
Completed

Safety and Pharmacokinetics of Dapivirine/Maraviroc Vaginal Ring

NCT01363037

Conditions
Blood-Borne Infections, Communicable Diseases, Genital Diseases, +11 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • The Fenway Institute/Fenway Community Health Boston, Massachusetts, United States
  • Magee-Womens Hospital of UPMC Pittsburgh, Pennsylvania, United States
View Trial Details

Related conditions